ANTX compared with SABS: revenue, margins and what each company keeps, and the suppliers and customers both name

ANTXAN2 Therapeutics, Inc.

Mkt capRevenueRevenue

SABSSAB Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

ANTXAN2 Therapeutics, Inc.

SABSSAB Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

ANTX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±60.5%▲+6.98%×0.12

SABS

No earnings history for SABS.

= impliedANTX realized, solidSABS realized, hatchedOne scale, both sides: full bar = 61%× = |realized| ÷ impliedSource: market data

ANTXAN2 Therapeutics, Inc.

4.00▲+1.14%· post 4.00

Mkt cap$150.9MRevenue—

SABSSAB Biotherapeutics, Inc.

3.02▲+2.59%· post 3.02

ClosedNov 6 '26

Mkt cap$273.0MRevenue$114,698Q4 FY24

Compare

ClosedNov 6 '26

ANTXAN2 Therapeutics, Inc.

SABSSAB Biotherapeutics, Inc.

4.00▲+1.14%post 4.00

Price

3.02▲+2.59%post 3.02

$150.9M

Mkt cap

$273.0M

—

Revenue

$114,698Q4 FY24

ANTX4.00▲+1.14%vsSABS3.02▲+2.59%ClosedNov 6 '26